United States - English - NLM (National Library of Medicine)

hospira, inc. - vincristine sulfate (unii: t5iro3534a) (vincristine - unii:5j49q6b70f) - vincristine sulfate injection is indicated in acute leukemia. vincristine sulfate injection has also been shown to be useful in combination with other oncolytic agents in hodgkin's disease, non–hodgkin's malignant lymphomas, rhabdomyosarcoma, neuroblastoma, and wilms' tumor. patients with the demyelinating form of charcot–marie–tooth syndrome should not be given vincristine sulfate injection. careful attention should be given to those conditions listed under warnings and precautions .

United States - English - NLM (National Library of Medicine)

hospira, inc. - vincristine sulfate (unii: t5iro3534a) (vincristine - unii:5j49q6b70f) - vincristine sulfate injection is indicated in acute leukemia. vincristine sulfate injection has also been shown to be useful in combination with other oncolytic agents in hodgkin's disease, non–hodgkin's malignant lymphomas, rhabdomyosarcoma, neuroblastoma, and wilms' tumor. patients with the demyelinating form of charcot–marie–tooth syndrome should not be given vincristine sulfate injection. careful attention should be given to those conditions listed under warnings and precautions .

Israel - English - Ministry of Health

abic marketing ltd, israel - vincristine sulfate - solution for injection - vincristine sulfate 1 mg/ml - vincristine - vincristine - vincristine may be used either as sole agent or in combination therapy in the treatment of acute leukemias. malignant lymphomas including hodgkin's disease lymphosarcoma and reticulum cell sarcoma, neuroblastoma, wilm's tumor, rhabdomyosarcoma.

Malta - English - Medicines Authority

pfizer hellas s.a. - vincristine sulfate - solution for injection - vincristine sulfate 1 milligram(s)/millilitre - antineoplastic agents

Malta - English - Medicines Authority

pfizer hellas s.a. 243 messoghion ave., neo psychiko 15451, athens, greece - vincristine sulfate - solution for infusion or injection - vincristine sulfate 1 mg/ml - antineoplastic agents

United States - English - NLM (National Library of Medicine)

talon therapeutics, inc. - vincristine sulfate (unii: t5iro3534a) (vincristine - unii:5j49q6b70f) - vincristine sulfate 5 mg in 5 ml - marqibo® is indicated for the treatment of adult patients with philadelphia chromosome-negative (ph-) acute lymphoblastic leukemia (all) in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies. this indication is based on overall response rate. clinical benefit such as improvement in overall survival has not been verified. marqibo is contraindicated in patients with demyelinating conditions including charcot-marie-tooth syndrome. marqibo is contraindicated in patients with hypersensitivity to vincristine sulfate or any of the other components of marqibo (vincristine sulfate liposome injection). marqibo is contraindicated for intrathecal administration. pregnancy category d [see warnings and precautions (5.9) ] based on its mechanism of action and findings from animal studies, marqibo can cause fetal harm when administered to pregnant women. if this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be

United States - English - NLM (National Library of Medicine)

teva parenteral medicines, inc. - vincristine sulfate (unii: t5iro3534a) (vincristine - unii:5j49q6b70f) - vincristine sulfate 1 mg in 1 ml - vincasar pfs is indicated in acute leukemia. vincasar pfs has also been shown to be useful in combination with other oncolytic agents in hodgkin’s disease, non-hodgkin’s malignant lymphomas, rhabdomyosarcoma, neuroblastoma, and wilms’ tumor. patients with the demyelinating form of charcot-marie-tooth syndrome should not be given vincasar pfs. careful attention should be given to those conditions listed under warnings  and precautions .

Ireland - English - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - vincristine sulfate - solution for injection/infusion - 1 micromole(s) - vinca alkaloids and analogues; vincristine

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - vincristine sulfate, quantity: 1 mg/ml - injection, solution - excipient ingredients: sulfuric acid; mannitol; water for injections; sodium hydroxide - vincristine sulfate is indicated in acute leukaemia - current practices of cancer chemotherapy involve the simultaneous use of several agents. for enhanced therapeutic effect without additive toxicity, agents with different dose-limiting clinical toxicities and different mechanisms of action are generally selected. it is rarely possible to achieve equally good results with single agent treatment. thus vincristine sulfate is often chosen as part of polychemotherapy because of its unique clinical toxicity (neuropathy). see dosage and administration for possible increased toxicity when used in combination therapy. it has been shown to be useful in combination with other oncolytic agents in hodgkin's disease, non-hodgkin's malignant lymphomas (lymphocytic, mixed-cell, histiocytic, undifferentiated, nodular and diffuse types), rhabdomyosarcoma, neuroblastoma, wilm's tumour, osteogenic sarcoma, mycosis fungoides, ewing's sarcoma, carcinoma of the uterine cervix, breast cancer, malignant melanoma, oat-cell carcinoma

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - vincristine sulfate, quantity: 1 mg/ml - injection, solution - excipient ingredients: water for injections; mannitol; sulfuric acid; sodium hydroxide - vincristine sulfate is indicated in acute leukaemia - current practices of cancer chemotherapy involve the simultaneous use of several agents. for enhanced therapeutic effect without additive toxicity, agents with different dose-limiting clinical toxicities and different mechanisms of action are generally selected. it is rarely possible to achieve equally good results with single agent treatment. thus vincristine sulfate is often chosen as part of polychemotherapy because of its unique clinical toxicity (neuropathy). see dosage and administration for possible increased toxicity when used in combination therapy. it has been shown to be useful in combination with other oncolytic agents in hodgkin's disease, non-hodgkin's malignant lymphomas (lymphocytic, mixed-cell, histiocytic, undifferentiated, nodular and diffuse types), rhabdomyosarcoma, neuroblastoma, wilm's tumour, osteogenic sarcoma, mycosis fungoides, ewing's sarcoma, carcinoma of the uterine cervix, breast cancer, malignant melanoma, oat-cell carcinoma